Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047671 · ClinicalTrials.gov registry record · Phase 4
Ethnic Variations in Antidepressant Response
A Phase 4 study of Depression, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
- 3
- Study locations
NCT00047671 is a Phase 4 study of Depression that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 400 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (49% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT00047671, a Phase 4 study of Depression, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
- 3
- Study locations
Study Summary
This 11-week study aims to determine how genetic factors affect the way African Americans and Caucasians with major depression respond to antidepressant medication \[citalopram (Celexa®)\].
Conditions Studied
Interventions
- DRUG Citalopram
Study Locations (3)
California
- Cedars-Sinai Medical Center, Department of Psychiatry, Clinical Trials Unit - Los Angeles
- UCLA/King-Drew - Los Angeles
- Harbor-UCLA Medical Center - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2002-06 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047671
The ClinicalTrials.gov registry entry for NCT00047671 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (49% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Citalopram is the first listed.
NCT00047671 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00047671 about?
NCT00047671 is a clinical study titled "Ethnic Variations in Antidepressant Response". This 11-week study aims to determine how genetic factors affect the way African Americans and Caucasians with major depression respond to antidepressant medication \[citalopram (Celexa®)\].
What is the current status of trial NCT00047671?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2002-06. Estimated completion is 2006-11.
What conditions does trial NCT00047671 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00047671?
The interventions under investigation include: Citalopram (DRUG).
Who is sponsoring clinical trial NCT00047671?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047671 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.